KENILWORTH (NJ) (dpa-AFX) - Merck & Co. Inc. (MRK), known as MSD outside of
the U.S. and Canada, announced Thursday it has initiated a Phase 3 clinical
trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor,
in combination with KEYTRUDA for the first-line treatment of certain patients
with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C
mutations and express PD-L1.

Merck has initiated a Phase 3, randomized, double-blind, multicenter clinical
trial (NCT06345729) evaluating once daily MK-1084 in combination with KEYTRUDA
administered once every three weeks compared with KEYTRUDA plus placebo.

The trial will enroll approximately 600 patients globally. The primary endpoints
of the study are progression-free survival and overall survival, and key
secondary endpoints include objective response rate and duration of response.

MK-1084 is being developed through a collaboration with Taiho Pharmaceutical Co.
Ltd and Astex Pharmaceuticals (UK), a wholly owned subsidiary of Otsuka
Pharmaceutical Co., Ltd. This collaboration was announced in January 2020.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX